News and Announcements
Novogen, The Future of Cancer Therapy, Releases Jun 2017 Newsletter
- Published June 07, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novogen (ASX: NRT) is an Australian oncology-focused biotechnology company that is pleased to present the company’s June 2017 Newsletter.
KEY TAKEAWAYS:
- In April, Novogen planned phase II clinical trial in relation to the most common and aggressive form of primary brain cancer. Novogen plans to focus the study on the almost two-thirds of patients.
- Approximately 200 patients will be recruited, and the company aims to start the study in the second half of calendar 2017.
- The study will be a randomised controlled trial and, if it is successful, it may offer an opportunity to approach FDA, the US regulatory agency, to discuss accelerated approval without waiting for a full phase III study.
- Phase I study of Cantrixil in ovarian cancer is progressing well. Five of the six participating hospitals are now open to recruitment. The timing of initial data is difficult to predict, because the design entails increasing doses until patients start to experience side effects, and this cannot be accurately predicted in advance.
- Novogen’s decision during April to terminate the development of Anisina, the lead program from the company’s anti-tropomyosin research. Despite the great work that has been done with Anisina, the emerging data did not, in our view, make it a promising candidate to take forward into human trials.
- In closing, the Novogen team remains tightly focused on delivering its programs.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
